Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the use of novel immunotherapies for the treatment of multiple myeloma. Prof. Einsele highlights data from the Phase Ib trial (NCT03836053) of AMG 420, which demonstrated promising efficacy results, and gives a broad overview of other bispecific T-cell engagers (BiTEs) which are being developed for the treatment of multiple myeloma. Prof. Einsele also discusses biallelic BCMA-loss for patients receiving BCMA-targeted BiTEs, and talks about the importance of developing BiTEs with alternate targets, such as GPRC5D and FcRH5. Finally, Prof. Einsele discusses the use of chimeric antigen receptor (CAR) T-cells for the treatment of multiple myeloma. This interview took place during the 2021 European Myeloma Network (EMN) congress.

свернуть